Miao Zhou | Precision Medicine | Best Researcher Award

Miao Zhou | Precision Medicine | Best Researcher Award

Prof. Miao Zhou at Guangdong Provincial People’s Hospital, China.

Dr. Miao Zhou is a distinguished oral and maxillofacial specialist, currently serving as Chief Physician and Associate Director at the Stomatology Department of Guangdong Provincial People’s Hospital. He is also a supervisor of postgraduate and postdoctoral researchers. An innovator in oral regenerative medicine, he founded the 3D Bioprinting and Regenerative Medicine Branch of the Guangdong Society of Biomedical Engineering. His pioneering research bridges clinical practice and cutting-edge biotechnology, advancing solutions for complex craniofacial conditions. With deep expertise in biomaterials, stem cells, and exosomes, Dr. Zhou continues to drive impactful research and medical education in the fields of maxillofacial rehabilitation and tissue engineering.

Publication Profile 

Scopus

Education

Dr. Miao Zhou earned his Ph.D. in 2009 from Peking University, one of China’s top-tier institutions, where he focused on maxillofacial rehabilitation using functional biomaterials and tissue engineering. His doctoral thesis explored clinical solutions for oral and maxillofacial defects through bio-integrative materials and scaffold systems. This strong academic foundation laid the groundwork for his later interdisciplinary innovations in regenerative medicine. In addition to his formal education, Dr. Zhou has participated in numerous continuing education programs and scientific collaborations, refining his expertise in 3D printing, stem cell therapy, and implantology, and training the next generation of specialists in advanced dental medicine.

Experience

With over 15 years of clinical and research experience, Dr. Miao Zhou is a Chief Physician and Associate Director at Guangdong Provincial People’s Hospital’s Stomatology Department. He supervises both postgraduates and postdocs, guiding translational research in tissue regeneration. He has served as Principal Investigator on numerous national and provincial-level projects, especially in the application of 3D-printed biomimetic scaffolds and exosomes. As a research leader, Dr. Zhou has pioneered innovations in craniomaxillofacial bone regeneration and soft tissue reconstruction. His clinical expertise, combined with academic leadership, positions him as a key influencer in oral regenerative therapy and personalized medical biomaterial development.

Awards 

Dr. Zhou has received numerous accolades, including the First Prize for Excellent Paper at the 6th China International & 9th China Academic Conference of Oral and Maxillofacial Surgery. His recognition reflects significant contributions to clinical and translational research. He has been honored by national bodies such as the National Natural Science Foundation of China and the Guangzhou Healthcare Innovation Program for his leadership in 3D bioprinting and regenerative medicine. As the founder of the 3D Bioprinting and Regenerative Medicine Branch under the Guangdong Society of Biomedical Engineering, his efforts have helped shape emerging medical frontiers and drive collaborative innovation.

Research Focus 

Dr. Zhou’s research centers on 3D-printed biomimetic scaffolds, stem cell therapy, and exosome-based interventions for oral and maxillofacial regeneration. His work explores how engineered tissues and cell-based therapies can reconstruct large jaw defects, restore bone function, and integrate with host tissues. His studies focus on osteoinduction, vascularization, and personalized medicine approaches using biocompatible materials. By leveraging cutting-edge printing technologies and biomolecular signaling pathways, Dr. Zhou aims to bridge gaps between laboratory research and clinical application—delivering impactful solutions for tissue repair and oral implantology. His interdisciplinary approach integrates biomaterials science, dentistry, and regenerative medicine to redefine patient care.

Publication Top Notes

  • An engineered M2 macrophage-derived exosomes-loaded electrospun biomimetic periosteum promotes cell recruitment, immunoregulation, and angiogenesis in bone regeneration
  • Osteogenically committed hUCMSCs-derived exosomes promote the recovery of critical-sized bone defects with enhanced osteogenic properties
  • 3WJ RNA Nanoparticles-Aptamer Functionalized Exosomes From M2 MacrophagesTarget BMSCs to Promote the Healing of Bone Fractures

Dr. ANTHOULA LAZARIS| Precision Medicine|Best Researcher Award

Dr. ANTHOULA LAZARIS, Precision Medicine,Best Researcher Award

Dr. ANTHOULA LAZARIS, at MCGILL UNIV. HEALTH CTR,Canada

PROFILE

scopus

📚 Early Academic Pursuits :

Anthoula Lazaris began her academic journey with a B.Sc. in Microbiology and Immunology from McGill University (1983-1986), where she developed a solid foundation in the biological sciences. She continued at McGill, earning a Ph.D. in Biochemistry from the Faculty of Medicine (1988-1992). Her postdoctoral studies took her to Leiden, The Netherlands, where she further honed her expertise in Medical Biochemistry (1992-1994). This robust educational background laid the groundwork for her illustrious career in academia and biotechnology.

🏢Professional Endeavors :

Lazaris has accumulated over 30 years of combined experience in academia and industry, holding management and senior-level positions. Currently, she is a scientist at the Research Institute of the McGill University Health Centre (RI-MUHC), focusing on metastatic and metabolic diseases with an emphasis on translational research. Her career highlights include:

  • Liver Disease Biobank: In 2011, Lazaris established a Liver Disease Biobank in collaboration with Dr. P Metrakos, collecting biospecimens from patients with liver-related diseases.
  • Quebec Extracellular Vesicle Consortium: She spearheaded this consortium with Drs. Rak and Olivier, demonstrating her leadership in collaborative research initiatives.
  • CIHR Training Grant: Lazaris co-wrote and secured a substantial CIHR training grant for the Goodman Cancer Centre, illustrating her proficiency in obtaining competitive funding.

🔬Contributions and Research Focus :

Lazaris’s research contributions span several critical areas:

  • Metastatic Disease: She focuses on colorectal cancer liver metastases (CRCLM), investigating molecular mechanisms to predict therapeutic responses and developing new biomarkers.
  • Translational Research: Her work bridges basic and clinical research, aiming to translate findings into precision therapies for cancer patients. Notably, her research on predictors of therapeutic responses to antiangiogenic agents has been groundbreaking.
  • Liver Diseases: Lazaris’s research also covers hepatocellular carcinoma, cholangiocarcinomas, and NAFLD/NASH, contributing to the broader understanding of these conditions.

🏆Accolades and Recognition :

Throughout her career, Lazaris has received numerous accolades:

  • Scientific American Award: In 2002, she was recognized in the category of Research Leader in Chemical and Materials for her work on transgenic animals producing spider silk.
  • Genome Canada White Paper: She spearheaded the writing of a white paper on “Disease Mechanisms,” which was integrated into Genome Quebec’s strategic plan.
  • Scientific Publications: Her research has been published in prestigious journals like Nature and Science, highlighting her contributions to molecular biology and oncology.

🌍Impact and Influence :

Lazaris’s work has had a profound impact on both the scientific community and public health:

  • Innovations in Biotechnology: She was part of the team that demonstrated the first expression of soluble spider silk, which can be spun into fibers with remarkable mechanical properties.
  • Transgenic Research Network: As the Executive Director of the Quebec Transgenic Research Network, Lazaris unified the capabilities of researchers across Quebec, securing significant funding and fostering collaborative research.
  • Cloned Animals: She was part of the team that generated the world’s first cloned goat and Canada’s first large transgenic animal, showcasing her pioneering contributions to genetic engineering.

🌟Legacy and Future Contributions :

Anthoula Lazaris’s legacy is marked by her pioneering research, leadership in collaborative scientific endeavors, and significant contributions to translational medicine. Her work continues to influence the fields of molecular biology, biotechnology, and cancer research. Looking forward, Lazaris is expected to further her contributions to personalized medicine, leveraging her extensive experience and innovative approach to address pressing challenges in healthcare. Her dedication to translational research and collaborative spirit ensures that her impact will be felt for years to come.

🎓Publication 

Predictive biomarker discovery in cancer using a unique AI model based on set theory

Hepatic stellate cell stearoyl co-A desaturase activates leukotriene B4 receptor 2 – β-catenin cascade to promote liver tumorigenesis

    • Authors :Sinha, S., Aizawa, S., Nakano, Y., Guccione, E., Tsukamoto, H.
    • Journal   :Nature Communications
    • Year       : 2023

Targeting Liver Metastases to Potentiate Immunotherapy in MS-Stable Colorectal Cancer—A Review of the Literature

  • Authors  :, Zlotnik, O., Krzywon, L., Bloom, J., Lazaris, A., Metrakos, P.
  • Journal    :Cancers
  • Year         :  2023

Isolation of extracellular vesicles from human plasma samples: The importance of controls

  • Authors  :Tsamchoe, M., Petrillo, S., Lazaris, A., Metrakos, P.
  • Journal   : Biotechnology Journal
  • Year        :   2023

A Retrospective Study on the Role of Metformin in Colorectal Cancer Liver Metastases

  • Authors  :Rada, M., Krzywon, L., Petrillo, S., Lazaris, A., Metrakos, P.
  • Journal   : Biotechnology 
  • Year        :  2023